81 results about "ELAV Proteins" patented technology

Provided are compositions and methods for treating survivin expressing cancers. The compositions contain peptide survivin peptide mimics with improved MHC-I binding characteristics. The method involves administering a survivin peptide mimic with improved MHC-I binding characteristics to an individual to effect inhibition of the growth of survivin expressing cancer cells in the individual.

The present invention relates to an improved method for the production of recombinant human blood clotting factors, in particular of factor VIII and factor IX, utilizing an immortalized human cell line stably expressing viral transcription activator proteins and carrying a vector having a promoter functionally linked to a DNA sequence coding for a blood coagulating factor, provided that said promoter is not a viral promoter which is stimulated by said viral transcription activator proteins; an immortalized human cell line carrying said vector, factor VIII muteins particularly suitable for the above production method; pharmaceutical compositions comprising such factor VIII muteins and the use of such factor VIII muteins for preparing a medicament for treating hemophilia.

In accordance with the present invention, there are provided selection systems and methods for screening for agents that control splicing of inteins in their native host protein (extein) or in homologous exteins. Specifically, there are provided positive genetic selection systems for the screening of agents which inhibit or activate protein splicing which comprise: a host cell containing a chromosomal gene encoding either a drug-resistant form of a target enzyme or a wild-type target enzyme, and a plasmid-borne gene encoding either a drug-sensitive form of the target enzyme, which is dominantly cytotoxic upon interaction with the drug, or a dominantly cytotoxic form of the target enzyme. In these systems the plasmid-borne gene contains an intein, and the inhibition or activation of splicing of the dominant cytotoxic form of the target enzyme by a given reagent results in the survival or death of the host cell. More specifically, positive genetic selection systems which utilize the M. xenopi GyrA intein or M. tuberculosis DnaB helicase intein are provided. Similar reporter systems utilizing native or homologous exteins and systems utilizing controllable inteins are provided, as are methods of controlling in vivo expression of proteins by modulating protein splicing with inhibiting or activating agents, and methods of controlling the delivery of proteinaceous drugs in vivo by modulating protein splicing.

A method of identifying a lead or candidate compound that modulates the activity of GTPase-Activating Protein SH3 Domain-Binding Proteins (G3BP) is provided, which includes determining whether a compound modulates the interaction between the N-terminal Nuclear Transport Factor 2-like (NTF2L) domain of G3BP and FGDF peptide of ubiquitin specific protease 10 (USP10) or non-structural protein 3 (nsP3).

The invention discloses an application of oridonin in preparing an activator of tumor-suppressor protein FBW7 (F-box and WD repeat domain containing 7). According to a large number of studies, oridonin can activate the expression of FBW7 protein and enhance the affinity of FBW7 protein to a substrate protein, so that FBW7-medicated ubiquitination degradation pathway is rapidly and efficiently activated. Oridonin target-degrades cancer protein such as c-Myc, cyclinE and mTOR through activation of the FBW7-medicated ubiquitination degradation pathway, so as to inhibit the growth of a variety oftumor cells and induce cell apoptosis. Oridonin is mainly derived from traditional Chinese medical material Rabdosia rubescens, is easy to prepared, has low toxicity to human body, and has high applicability.

The invention discloses a CRISPR-Cas13 nucleic acid detection kit based on a lightening type RNA aptamer. The kit comprises the lightening type RNA aptamer, Cas13 protein, crRNA and nucleic acid dye; the lightening type RNA aptamer can be combined with nucleic acid dye to emit fluorescence, and if the lightening type RNA aptamer is sheared by Cas13 protein, fluorescence is quenched; the crRNA is a section of RNA, the crRNA and Cas13 protein can form a crRNA-Cas13 compound, and after the Cas 13-crRNA is combined with a target RNA sequence, the enzyme digestion activity of the Cas13 protein is activated, and an RNA aptamer is excised. The kit can detect living pathogens and RNA markers by detecting RNA, and compared with an existing nucleic acid detection method based on CRISPR-Cas13, the method does not depend on reverse transcription and nucleic acid amplification, target RNA sequence detection is completed in one step, the detection cost is low, the operation steps are simple, high specificity and sensitivity can be guaranteed, and industrial application is facilitated.

The invention relates to a novel application of gamma-secretase activated protein gene and/or protein coded by gamma-secretase activated protein gene. According to the application disclosed by the invention, by screening acute myelogenous leukemia (AML) prognosis related molecular markers, the screened gamma-secretase activated protein gene (GSAP) is closely related to the prognosis of acute myelogenous leukemia patients; the high expression of the GSAP prompts that the prognosis of the acute myelogenous leukemia patient is poor; the GSAP is related to FAB typing and cytogenetics risk stratification of an acute myelogenous leukemia patient; and the GSAP may participate in the disease progress of acute myelogenous leukemia through various ways such as PI3K-AKT, TLR and the like. The GSAP is used for preparing a treatment drug or a diagnostic reagent and a prognosis detection reagent for acute myelogenous leukemia.

The invention relates to application of peptide vaccines and microgene vaccines based on CTL epitope peptides of FAPalpha, and belongs to the field of tumor peptide vaccines and DNA vaccines with fibroblast activator protein alpha as a target. The invention discloses an FAPalpha derived antitumor epitope peptide FAP.291 and a mimic peptide FAP.291I9 of the FAPalpha derived antitumor epitope peptide FAP.291 and application of microgene DNA vaccines constructed by the FAPalpha derived antitumor epitope peptide FAP.291 and the mimic peptide FAP.291I9 of the FAPalpha derived antitumor epitope peptide FAP.291 in preparation of tumor therapeutic vaccines. Through screening and identification, the epitope FAP.291 and the mimic epitope FAP.291I9 are determined, so that a specific CTL reaction in BALB/c mice can be effectively activated. The invention further relates to application of the vaccines using FAP.291 and FAP.291I9 small peptides in combination with adjuvants and constructing microgene forms of the FAP.291 and FAP.291I9 small peptides in tumor prevention.

The invention relates to a urate oxidase with catalytic activity. A 'resurrection' human urate oxidase amino acid sequence with catalytic activity, a nucleotide sequence for encoding the protein, a vector containing the nucleotide sequence and a host cell containing the vector are obtained by adopting genetic engineering technology modification. The invention also discloses a method for preparing the resurrection protein by using a genetic engineering technology, and a product obtained by modifying the protein. The urate oxidase has good enzymatic activity and stability, the coding sequence of the urate oxidase maintains high homology with human urate oxidase pseudogenes, and the urate oxidase has good prospects in preparation of low-immunogenicity or even immunogenicity-free uric acid lowering drugs or pharmaceutical compositions.